{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/13367"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/13367","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Applying Phage Display to Screen a Library of α1-Proteinase Inhibitor Mutants for Improved Thrombin Binding Activity","abstract":"<p>α<sub>1</sub>-proteinase inhibitor (α<sub>1</sub>-PI) is the most abundant serine protease inhibitor (serpin) in plasma. The α<sub>1</sub>-PI M358R mutant exhibits greatly increased rates of thrombin inhibition compared to wild type α<sub>1</sub>-PI, which predominantly inhibits neutrophil elastase. M358R (P1) lies at the reactive centre (P1-P1’) bond of the reactive centre loop (RCL) of α<sub>1</sub>-PI, cleaved by cognate proteases as they become trapped in the serpin-type inhibitory complex. The relationship between RCL structure and serpin inhibitor function is incompletely understood and has not been subjected to saturation mutagenesis. α<sub>1</sub>-PI M358R is a less potent inhibitor of thrombin than natural thrombin-inhibitory serpins, suggesting room for engineered improvement into an antithrombotic protein drug.</p> <p>Phage display is a powerful tool for screening mutant protein libraries, but only one serpin (PAI-1) has previously been mutated and expressed in this manner. In this study the T7Select10-3b (Novagen) phage display system was used to express α<sub>1</sub>-PI variants and PAI-1, fused to the first 348 residues of the T7 10B coat protein. Following confirmation that α<sub>1</sub>-PI M358R retained inhibitory activity when fused to T7Select10-3b phage, this system was used to express a library of α<sub>1</sub>-PI mutant proteins with all possible codon combinations at positions P2 (P357) and P1 (M358) (441 mutants). The library was biopanned using a novel technique in order to amplify only the α<sub>1</sub>-PI P2P1 mutants capable of forming stable complexes with thrombin. The P357/M358R mutant was the only P2P1 mutant enriched, indicating that the α<sub>1</sub>-PI M358R protein has the optimal P2P1 sequence for thrombin inhibition.</p> <p>A second T7Select10-3b library of α<sub>1</sub>-PI mutant proteins was generated to identify the optimal sequence at positions P7 through to P3 (amino acids 352-356) for thrombin inhibition. The P2 and P1 positions were maintained at P357/M358R, while all possible codon combinations at positions P7 through to P3 were represented (>4.08 million mutants). The library was biopanned using the protocol developed for the P2P1 library, before sequences were inserted into an <em>E. coli</em> expression vector and α<sub>1</sub>-PI M358R P7-P3 mutants were screened for thrombin inhibitory activity. 80 individual colonies were screened, yielding 22 unique P7-P3 mutants with thrombin inhibitory activity greater than the M358R RCL sequence. The consensus observed in sequences with improved activity matched thrombin’s known substrate specificity and also general RCL trends: P7-Not Aromatic/P6-Hydrophobic/P5-T or S/P4-Hydrophobic/P3-Not Aromatic.</p> <p>Kinetic characterization of selected mutants with improved thrombin inhibitory activity yielded two mutants, P7-P3 sequence DITMA and AAFVS, with a second order rate constant of 1.0 x 10<sup>6</sup> M<sup>-1</sup>s<sup>-1</sup>. This represents a >2-fold increase in the rate of thrombin inhibition versus α<sub>1</sub>-PI M358R. Both the DITMA and AAFVS mutants were found to have a lower stoichiometry of inhibition compared to α<sub>1</sub>-PI M358R, indicating that an improved thrombin inhibitory mechanism was also enriched during biopanning.</p> <p>These findings suggest that based on the scaffold of the α<sub>1</sub>-PI protein, improved thrombin inhibitory activity can be engineered and selected via phage display. Additionally, this work represents a proof-of-principle for the application of this system to screen libraries of up to 10 million mutants in order to better engineer serpins towards a desired activity.</p>","abstract_html":"&lt;p&gt;α&lt;sub&gt;1&lt;/sub&gt;-proteinase inhibitor (α&lt;sub&gt;1&lt;/sub&gt;-PI) is the most abundant serine protease inhibitor (serpin) in plasma. The α&lt;sub&gt;1&lt;/sub&gt;-PI M358R mutant exhibits greatly increased rates of thrombin inhibition compared to wild type α&lt;sub&gt;1&lt;/sub&gt;-PI, which predominantly inhibits neutrophil elastase. M358R (P1) lies at the reactive centre (P1-P1’) bond of the reactive centre loop (RCL) of α&lt;sub&gt;1&lt;/sub&gt;-PI, cleaved by cognate proteases as they become trapped in the serpin-type inhibitory complex. The relationship between RCL structure and serpin inhibitor function is incompletely understood and has not been subjected to saturation mutagenesis. α&lt;sub&gt;1&lt;/sub&gt;-PI M358R is a less potent inhibitor of thrombin than natural thrombin-inhibitory serpins, suggesting room for engineered improvement into an antithrombotic protein drug.&lt;/p&gt; &lt;p&gt;Phage display is a powerful tool for screening mutant protein libraries, but only one serpin (PAI-1) has previously been mutated and expressed in this manner. In this study the T7Select10-3b (Novagen) phage display system was used to express α&lt;sub&gt;1&lt;/sub&gt;-PI variants and PAI-1, fused to the first 348 residues of the T7 10B coat protein. Following confirmation that α&lt;sub&gt;1&lt;/sub&gt;-PI M358R retained inhibitory activity when fused to T7Select10-3b phage, this system was used to express a library of α&lt;sub&gt;1&lt;/sub&gt;-PI mutant proteins with all possible codon combinations at positions P2 (P357) and P1 (M358) (441 mutants). The library was biopanned using a novel technique in order to amplify only the α&lt;sub&gt;1&lt;/sub&gt;-PI P2P1 mutants capable of forming stable complexes with thrombin. The P357/M358R mutant was the only P2P1 mutant enriched, indicating that the α&lt;sub&gt;1&lt;/sub&gt;-PI M358R protein has the optimal P2P1 sequence for thrombin inhibition.&lt;/p&gt; &lt;p&gt;A second T7Select10-3b library of α&lt;sub&gt;1&lt;/sub&gt;-PI mutant proteins was generated to identify the optimal sequence at positions P7 through to P3 (amino acids 352-356) for thrombin inhibition. The P2 and P1 positions were maintained at P357/M358R, while all possible codon combinations at positions P7 through to P3 were represented (&gt;4.08 million mutants). The library was biopanned using the protocol developed for the P2P1 library, before sequences were inserted into an &lt;em&gt;E. coli&lt;/em&gt; expression vector and α&lt;sub&gt;1&lt;/sub&gt;-PI M358R P7-P3 mutants were screened for thrombin inhibitory activity. 80 individual colonies were screened, yielding 22 unique P7-P3 mutants with thrombin inhibitory activity greater than the M358R RCL sequence. The consensus observed in sequences with improved activity matched thrombin’s known substrate specificity and also general RCL trends: P7-Not Aromatic/P6-Hydrophobic/P5-T or S/P4-Hydrophobic/P3-Not Aromatic.&lt;/p&gt; &lt;p&gt;Kinetic characterization of selected mutants with improved thrombin inhibitory activity yielded two mutants, P7-P3 sequence DITMA and AAFVS, with a second order rate constant of 1.0 x 10&lt;sup&gt;6&lt;/sup&gt; M&lt;sup&gt;-1&lt;/sup&gt;s&lt;sup&gt;-1&lt;/sup&gt;. This represents a &gt;2-fold increase in the rate of thrombin inhibition versus α&lt;sub&gt;1&lt;/sub&gt;-PI M358R. Both the DITMA and AAFVS mutants were found to have a lower stoichiometry of inhibition compared to α&lt;sub&gt;1&lt;/sub&gt;-PI M358R, indicating that an improved thrombin inhibitory mechanism was also enriched during biopanning.&lt;/p&gt; &lt;p&gt;These findings suggest that based on the scaffold of the α&lt;sub&gt;1&lt;/sub&gt;-PI protein, improved thrombin inhibitory activity can be engineered and selected via phage display. Additionally, this work represents a proof-of-principle for the application of this system to screen libraries of up to 10 million mutants in order to better engineer serpins towards a desired activity.&lt;/p&gt;","abstract_has_math":false,"creators":["Scott, Benjamin M."],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Medical Sciences (Thrombosis & Haemostasis & Atherosclerosis)","school":null,"contributors":[],"advisors":["Sheffield, William P.","Junop, Murray","Bramson, Jonathan"],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-10","date_published":"2013-10","updated_at":"2026-11-18T19:33:53Z","subjects":["protein engineering","thrombin","phage display","coagulation","serpin","thrombin inhibitor","Amino Acids, Peptides, and Proteins"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/15282"],"render_values":[{"text":"https://doi.org/10.71548/15282","href":"https://doi.org/10.71548/15282","code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/8189","9130","4492736"],"render_values":[{"text":"opendissertations/8189","href":null,"code":true},{"text":"9130","href":null,"code":true},{"text":"4492736","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/13367","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/13367","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F13367","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Sheffield, William P.","Junop, Murray","Bramson, Jonathan"]},{"key":"dc:contributor.department","label":"Department","values":["Medical Sciences (Thrombosis & Haemostasis & Atherosclerosis)"]},{"key":"dc:creator","label":"Author","values":["Scott, Benjamin M."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-06-18T17:03:45Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-06-18T17:03:45Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2013-08-23"]},{"key":"dc:date.issued","label":"Date","values":["2013-10"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["protein engineering","thrombin","phage display","coagulation","serpin","thrombin inhibitor","Amino Acids, Peptides, and Proteins"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/8189","9130","4492736"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/13367","https://doi.org/10.71548/15282"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p>α<sub>1</sub>-proteinase inhibitor (α<sub>1</sub>-PI) is the most abundant serine protease inhibitor (serpin) in plasma. The α<sub>1</sub>-PI M358R mutant exhibits greatly increased rates of thrombin inhibition compared to wild type α<sub>1</sub>-PI, which predominantly inhibits neutrophil elastase. M358R (P1) lies at the reactive centre (P1-P1’) bond of the reactive centre loop (RCL) of α<sub>1</sub>-PI, cleaved by cognate proteases as they become trapped in the serpin-type inhibitory complex. The relationship between RCL structure and serpin inhibitor function is incompletely understood and has not been subjected to saturation mutagenesis. α<sub>1</sub>-PI M358R is a less potent inhibitor of thrombin than natural thrombin-inhibitory serpins, suggesting room for engineered improvement into an antithrombotic protein drug.</p> <p>Phage display is a powerful tool for screening mutant protein libraries, but only one serpin (PAI-1) has previously been mutated and expressed in this manner. In this study the T7Select10-3b (Novagen) phage display system was used to express α<sub>1</sub>-PI variants and PAI-1, fused to the first 348 residues of the T7 10B coat protein. Following confirmation that α<sub>1</sub>-PI M358R retained inhibitory activity when fused to T7Select10-3b phage, this system was used to express a library of α<sub>1</sub>-PI mutant proteins with all possible codon combinations at positions P2 (P357) and P1 (M358) (441 mutants). The library was biopanned using a novel technique in order to amplify only the α<sub>1</sub>-PI P2P1 mutants capable of forming stable complexes with thrombin. The P357/M358R mutant was the only P2P1 mutant enriched, indicating that the α<sub>1</sub>-PI M358R protein has the optimal P2P1 sequence for thrombin inhibition.</p> <p>A second T7Select10-3b library of α<sub>1</sub>-PI mutant proteins was generated to identify the optimal sequence at positions P7 through to P3 (amino acids 352-356) for thrombin inhibition. The P2 and P1 positions were maintained at P357/M358R, while all possible codon combinations at positions P7 through to P3 were represented (>4.08 million mutants). The library was biopanned using the protocol developed for the P2P1 library, before sequences were inserted into an <em>E. coli</em> expression vector and α<sub>1</sub>-PI M358R P7-P3 mutants were screened for thrombin inhibitory activity. 80 individual colonies were screened, yielding 22 unique P7-P3 mutants with thrombin inhibitory activity greater than the M358R RCL sequence. The consensus observed in sequences with improved activity matched thrombin’s known substrate specificity and also general RCL trends: P7-Not Aromatic/P6-Hydrophobic/P5-T or S/P4-Hydrophobic/P3-Not Aromatic.</p> <p>Kinetic characterization of selected mutants with improved thrombin inhibitory activity yielded two mutants, P7-P3 sequence DITMA and AAFVS, with a second order rate constant of 1.0 x 10<sup>6</sup> M<sup>-1</sup>s<sup>-1</sup>. This represents a >2-fold increase in the rate of thrombin inhibition versus α<sub>1</sub>-PI M358R. Both the DITMA and AAFVS mutants were found to have a lower stoichiometry of inhibition compared to α<sub>1</sub>-PI M358R, indicating that an improved thrombin inhibitory mechanism was also enriched during biopanning.</p> <p>These findings suggest that based on the scaffold of the α<sub>1</sub>-PI protein, improved thrombin inhibitory activity can be engineered and selected via phage display. Additionally, this work represents a proof-of-principle for the application of this system to screen libraries of up to 10 million mutants in order to better engineer serpins towards a desired activity.</p>"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Health Sciences (MSc)"]},{"key":"dc:title","label":"Title","values":["Applying Phage Display to Screen a Library of α1-Proteinase Inhibitor Mutants for Improved Thrombin Binding Activity"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Sheffield, William P.","Junop, Murray","Bramson, Jonathan"],"dc:contributor.department":["Medical Sciences (Thrombosis & Haemostasis & Atherosclerosis)"],"dc:creator":["Scott, Benjamin M."],"dc:date.accessioned":["2014-06-18T17:03:45Z"],"dc:date.available":["2014-06-18T17:03:45Z"],"dc:date.created":["2013-08-23"],"dc:date.issued":["2013-10"],"dc:description.abstract":["<p>α<sub>1</sub>-proteinase inhibitor (α<sub>1</sub>-PI) is the most abundant serine protease inhibitor (serpin) in plasma. The α<sub>1</sub>-PI M358R mutant exhibits greatly increased rates of thrombin inhibition compared to wild type α<sub>1</sub>-PI, which predominantly inhibits neutrophil elastase. M358R (P1) lies at the reactive centre (P1-P1’) bond of the reactive centre loop (RCL) of α<sub>1</sub>-PI, cleaved by cognate proteases as they become trapped in the serpin-type inhibitory complex. The relationship between RCL structure and serpin inhibitor function is incompletely understood and has not been subjected to saturation mutagenesis. α<sub>1</sub>-PI M358R is a less potent inhibitor of thrombin than natural thrombin-inhibitory serpins, suggesting room for engineered improvement into an antithrombotic protein drug.</p> <p>Phage display is a powerful tool for screening mutant protein libraries, but only one serpin (PAI-1) has previously been mutated and expressed in this manner. In this study the T7Select10-3b (Novagen) phage display system was used to express α<sub>1</sub>-PI variants and PAI-1, fused to the first 348 residues of the T7 10B coat protein. Following confirmation that α<sub>1</sub>-PI M358R retained inhibitory activity when fused to T7Select10-3b phage, this system was used to express a library of α<sub>1</sub>-PI mutant proteins with all possible codon combinations at positions P2 (P357) and P1 (M358) (441 mutants). The library was biopanned using a novel technique in order to amplify only the α<sub>1</sub>-PI P2P1 mutants capable of forming stable complexes with thrombin. The P357/M358R mutant was the only P2P1 mutant enriched, indicating that the α<sub>1</sub>-PI M358R protein has the optimal P2P1 sequence for thrombin inhibition.</p> <p>A second T7Select10-3b library of α<sub>1</sub>-PI mutant proteins was generated to identify the optimal sequence at positions P7 through to P3 (amino acids 352-356) for thrombin inhibition. The P2 and P1 positions were maintained at P357/M358R, while all possible codon combinations at positions P7 through to P3 were represented (>4.08 million mutants). The library was biopanned using the protocol developed for the P2P1 library, before sequences were inserted into an <em>E. coli</em> expression vector and α<sub>1</sub>-PI M358R P7-P3 mutants were screened for thrombin inhibitory activity. 80 individual colonies were screened, yielding 22 unique P7-P3 mutants with thrombin inhibitory activity greater than the M358R RCL sequence. The consensus observed in sequences with improved activity matched thrombin’s known substrate specificity and also general RCL trends: P7-Not Aromatic/P6-Hydrophobic/P5-T or S/P4-Hydrophobic/P3-Not Aromatic.</p> <p>Kinetic characterization of selected mutants with improved thrombin inhibitory activity yielded two mutants, P7-P3 sequence DITMA and AAFVS, with a second order rate constant of 1.0 x 10<sup>6</sup> M<sup>-1</sup>s<sup>-1</sup>. This represents a >2-fold increase in the rate of thrombin inhibition versus α<sub>1</sub>-PI M358R. Both the DITMA and AAFVS mutants were found to have a lower stoichiometry of inhibition compared to α<sub>1</sub>-PI M358R, indicating that an improved thrombin inhibitory mechanism was also enriched during biopanning.</p> <p>These findings suggest that based on the scaffold of the α<sub>1</sub>-PI protein, improved thrombin inhibitory activity can be engineered and selected via phage display. Additionally, this work represents a proof-of-principle for the application of this system to screen libraries of up to 10 million mutants in order to better engineer serpins towards a desired activity.</p>"],"dc:description.degree":["Master of Health Sciences (MSc)"],"dc:identifier.other":["opendissertations/8189","9130","4492736"],"dc:identifier.uri":["http://hdl.handle.net/11375/13367","https://doi.org/10.71548/15282"],"dc:subject":["protein engineering","thrombin","phage display","coagulation","serpin","thrombin inhibitor","Amino Acids, Peptides, and Proteins"],"dc:title":["Applying Phage Display to Screen a Library of α1-Proteinase Inhibitor Mutants for Improved Thrombin Binding Activity"],"dc:type":["thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:33:53Z"}